HCL-GROUP
21.5.2024 14:05:33 CEST | Business Wire | Press release
HCL Group, a global conglomerate, and UpLink, the open innovation platform of the World Economic Forum, announced the third challenge of the Aquapreneur Innovation Initiative, the “Tackling Water Pollution Challenge.” This announcement was made during the 10th World Water Forum in Bali, Indonesia. The application deadline for submission is 31st August 2024. The winners will be announced in January 2025, and the top 10 winners will receive a total financial award of 1.75M CHF. Detailed information and eligibility requirements can be accessed through the following link.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521731615/en/
Sundar Mahalingam, President of Strategy at HCL Corporation, unveils Challenge 3 of the Aquapreneur Innovation Initiative at the World Water Forum in Bali (Photo: Business Wire)
Important Dates to Note |
|
21 May to 31st August 2024 |
Open for submissions |
1st September to 1st November 2024 |
Review and selection process |
January 2025 |
Announcement of the Top Innovators |
The Innovation Challenge aims to empower changemakers who are pioneering groundbreaking technologies, strategies, and approaches to conserve, manage, and protect water resources. HCL has pledged US$15 million over five years till 2027 to bolster entrepreneurs focusing on water-related endeavors. The challenge will focus on the intersection of the quality and environmental impacts of water, with the key aspects including:
-
Preventing contamination of water at source- Source control aims to prevent or minimize the introduction of pollutants and contaminants at their source. Solutions may be aimed at contaminants from industry, agriculture, stormwater etc., and could include real-time monitoring and sensor networks, advanced filtration, and nature-based solutions.
-
Monitoring and treating onsite industrial wastewater- Water is a core component in many industrial processes from manufacturing, cleaning and sanitation, mining, and cooling. Technological solutions offer a way to monitor water quality and reduce water contamination, minimize environmental impacts and move towards zero liquid discharge for industries.
-
Optimising urban infrastructure public water and wastewater treatment systems- Water and wastewater treatment infrastructure upgrades are expensive and the costs are climbing. This area will target a broad range of technological solutions that can unlock value by improving efficiency, reducing costs, and ensuring compliance.
- Offering water quality solutions for households- The convergence of environmental awareness, cost considerations, regulatory pressures, and health concerns is driving the increasing popularity of personal water quality solutions among individuals and households. Technological solutions may include portable water testing, point-of-use water purification, and apps for crowd-sourcing water quality data.
While launching the challenge, Sundar Mahalingam, President of Strategy at HCL Corporation said, "At HCL, we understand the power of innovation, and through our partnership with UpLink, we are empowering Aquapreneurs to scale their solutions and drive meaningful impact. The first two editions of the Aquapreneur Innovation Initiative have demonstrated remarkable success, with participating entrepreneurs showcasing solutions that address critical water challenges. The Aquapreneurs from the first challenge have raised $54.5 million grants and venture capital funding since joining the cohort. This validates the effectiveness of the initiative in nurturing and supporting innovative ideas that address critical water challenges. We are, therefore, thrilled to announce the third challenge, aiming to engage a broader network of Aquapreneur globally.”
John Dutton, Head of UpLink, World Economic Forum, added, “At UpLink, we believe innovation and collaboration are key to overcoming the complex water challenges facing our planet. UpLink and HCL Group will tap into the world’s brightest entrepreneurial minds working in this sector to help minimize the problem of freshwater loss by connecting them to essential resources, experts, and funding. The Tackling Water Pollution Challenge will ensure that the most scalable solutions are deployed to ensure that this vital resource is sustainably available to all.”
Evaluation and selection criteria for 3rd year includes:
-
Business viability
- Demonstrates a financially sustainable business model with a clear revenue approach.
- Presents a funding history and potential for investment.
- Identifies and manages external risks effectively.
- Shows alignment with market demand locally or globally.
-
Has a legal entity and operational plan for financial sustainability.
-
Commitment to Deliver Impact
- Shows sustainable impact benefiting multiple sectors including society and the environment.
- Aligns with long-term water agenda goals.
- Utilizes a robust framework for impact measurement and verification.
-
Transparently tracks metrics and adheres to relevant standards.
-
Solution Novelty and Replicability
- Offers unique aspects in product/service, pricing, partnerships, or business model.
- Provides evidence of concept feasibility and replicability across different contexts.
As water scarcity and pollution continue to pose significant threats to communities and ecosystems globally, the Aquapreneur Innovation Initiative seeks to harness the power of innovation to create sustainable solutions. Selected participants will receive mentorship, funding support, access to networks, media visibility, and other resources to scale their initiatives and maximize their impact.
About HCL
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978, well before its global peers. Today, the HCL enterprise has a presence across varied sectors that include technology, healthcare and talent management solutions and comprises three companies – HCL Infosystems, HCLTech and HCL Healthcare. The enterprise generates annual revenues of over US$13.3 billion with 227,481 employees operating across 60 countries. For further information, visit www.hcl.com
About UpLink
UpLink is the open innovation platform of the World Economic Forum, dedicated to unlocking an ‘entrepreneur revolution’ to support positive systemic change for people and planet. Launched at the Forum’s Annual Meeting in Davos in January 2020 with support from Salesforce and Deloitte, UpLink is now a thriving ecosystem of entrepreneurs, investors and experts, who are collaborating around innovation for the UN Sustainable Development Goals.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521731615/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
